[Skip to Navigation]
Views 349
Citations 0
Ophthalmic Images
December 10, 2020

Iris Metastasis Regression Following Osimertinib Treatment

Author Affiliations
  • 1Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • 2College of Medicine, Chang Gung University, Taoyuan, Taiwan
  • 3Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
JAMA Ophthalmol. 2020;138(12):e202095. doi:10.1001/jamaophthalmol.2020.2095

A 75-year-old woman presented with a pinkish lesion in her right iris. She had been diagnosed with lung adenocarcinoma with an epidermal growth factor receptor T790M (c.2369C>T) sequence variation in exon 20 and undergone thoracoscopic lobectomy 7 years earlier. Her visual acuity was not affected, and her intraocular pressure level was normal. A slitlamp biomicroscopic examination showed a localized lesion extending from 5 o’clock to 8 o’clock in the right iris (Figure, A). Whole-body computed tomography revealed focal lung cancer recurrence with local and distant lymph node metastases. After she received treatment with osimertinib (a third-generation epidermal growth factor receptor inhibitor) for 3 months, the iris tumor completely regressed (Figure, B). During 15 months of follow-up, there was no recurrence of lung cancer or iris metastasis. She continues to receive osimertinib up to the present.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words